CareDx (CDNA) Stock Price

CareDx Price

NASDAQ·CLOSED
63.04
​
Market closed

Revenue has compounded at 42.9% per year over the past 20 years to 379.81 M USD. CareDx's net margin stands at -5.6%, up from -10.3% several years earlier. Analysts set a median price target of 60.00 USD, implying 4.8% below the current price. Of 13 analysts, 9 rate the stock a buy — an overall Buy consensus.

CareDx stock price

Access this data via the Eulerpool API

CareDx business model & stock analysis

CareDx Inc is a US-based company specializing in diagnostic solutions for the transplantation industry. The company was founded in 1998 and is at the forefront of developing tests for transplant patients.

Frequently asked questions about CareDx

The business model of CareDx Inc. revolves around providing personalized medicine solutions for transplant patients. CareDx utilizes advanced diagnostic tools and technology to improve the outcome of organ transplant procedures. The company specializes in developing and delivering innovative molecular diagnostic solutions, including its flagship product, AlloSure, which helps assess the health and function of transplanted organs. CareDx Inc. also offers a comprehensive portfolio of transplant surveillance products and services to aid physicians in managing patients post-transplant. With a focus on organ transplant patients, CareDx aims to enhance patient care and optimize transplant outcomes through its cutting-edge molecular diagnostic solutions.

CareDx Inc is primarily active in the biotechnology and healthcare industries.

The main competitors of CareDx Inc in the market include companies such as Natera Inc, Illumina Inc, and Thermo Fisher Scientific Inc.

CareDx Inc is a leading precision medicine company focused on transforming patient care through diagnostic solutions. Established in 1998, CareDx specializes in transplant diagnostics, offering a comprehensive suite of products and services to assess the health of transplanted organs. The company's innovative technologies, such as AlloSure and AlloMap, enable healthcare providers to monitor transplant patients and personalize treatment plans. With a strong commitment to improving outcomes for transplant recipients, CareDx has played a significant role in advancing transplant medicine. CareDx Inc continues to be a trusted name in the healthcare industry, providing valuable insights and solutions for clinicians and patients alike.

CareDx Inc has achieved several significant milestones since its inception. The company has made notable advancements in the field of transplant diagnostics. It has successfully developed and commercialized innovative testing solutions, such as AlloSure and AlloMap, which help healthcare professionals monitor organ transplant recipient's immune system. CareDx Inc has also expanded its portfolio with the acquisition of other diagnostic technologies, allowing it to offer a comprehensive range of solutions. Additionally, the company has collaborated with renowned transplant centers and research institutions, further enhancing its expertise and reputation in the field. These accomplishments demonstrate CareDx Inc's commitment to improving transplant patient outcomes through cutting-edge diagnostics.

CareDx Inc is primarily present in the United States, with its headquarters located in Brisbane, California. As a leading precision medicine company, CareDx focuses on improving patient outcomes through advancing diagnostic solutions for transplant patients. With a wide range of innovative products and services, CareDx aims to optimize transplant management and enhance long-term patient care. While CareDx operates globally, its primary presence remains concentrated within the United States.

CareDx Inc represents values of innovation, patient-centricity, and excellence in personalized medicine. The company is committed to transforming patient care through transplant diagnostics and novel digital health solutions. CareDx emphasizes collaboration with clinicians and industry partners to deliver breakthrough technologies that improve outcomes for transplant patients. With a focus on providing accurate, timely, and actionable information, CareDx strives to empower healthcare professionals with the tools needed to make informed decisions and improve patient lives. By leveraging their expertise in genomics and diagnostic testing, CareDx is driving advancements in the field of transplantation and leading the way in improving the standard of care.

Analysts currently set an average price target of 56.67 USD for the CareDx stock (median: 60.00 USD), implying -10.1 % versus the latest price. The consensus is based on 13 analyst ratings.

13 analysts currently rate the CareDx stock: 9 recommend buying, 4 holding and 0 selling. For 2026, analysts expect CareDx to generate revenue of 495.12 M USD and earnings per share of 1.20 USD.

Converted at the current exchange rate, the CareDx share trades at 56.29 EUR (63.04 USD).

The CareDx share (CDNA) is listed on 5 stock exchanges, including: NASDAQ (CDNA), Frankfurt (1K9), München (1K9.MU), Düsseldorf (1K9.DU).

CareDx Inc. is a leading company in the field of diagnostic medicine and offers a wide range of products and services for transplant patients. The company is headquartered in Brisbane, California and specializes in the development, manufacturing, and marketing of solutions for monitoring and treating transplant patients. CareDx Inc. is divided into various divisions, each offering different products and services. Here are some of the main divisions of the company: Transplant Diagnostics: This division of CareDx Inc. offers a variety of tests for monitoring transplant patients. These include diagnostic tests for identifying donor and recipient characteristics, blood tests for monitoring immunosuppression, and molecular tests for determining rejection rates. These tests help doctors monitor the status of the transplant and treat it specifically. Transplant Patient Monitoring: This division of CareDx Inc. offers monitoring systems for transplant patients. These systems allow doctors to continuously monitor the patient's condition and detect early signs of rejection or other complications. The systems include devices for measuring weight, blood pressure, pulse, and other vital parameters. Transplant Care: This division of CareDx Inc. offers a wide range of services for transplant patients. These include personal care, patient and caregiver education, and support for accessing treatment services. The goal of these services is to provide comprehensive support to patients and help them achieve optimal outcomes after transplantation. Transplant Business: This division of CareDx Inc. offers specialized products and services for transplant centers and hospitals. These include training for medical staff, consulting services for best practices in transplant medicine, and specialized software for monitoring transplant patients. CareDx Inc. offers a wide range of products and services for transplant patients, all aimed at improving patient outcomes and quality of life. The company has a strong research and development department that continuously strives to develop innovative products and technologies to improve transplant medicine. The company works closely with transplant centers and medical professionals to ensure that patients' needs are met and that they receive optimal care. SEO Optimization: CareDx Inc. is a leading company in the field of diagnostic medicine and offers a wide range of products and services for transplant patients. The company is divided into various divisions, each offering different products and services. CareDx Inc. has a strong research and development department that continuously strives to develop innovative products and technologies. The company works closely with transplant centers and medical professionals to ensure that patients' needs are met. If you are looking for high-quality products and services for transplant patients, then CareDx Inc. is your best choice.

The expected revenue of CareDx is 495.12 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of CareDx is 61.60 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of CareDx is currently 52.32. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CareDx stock.

The price-to-sales ratio (P/S) of CareDx is currently 6.51. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CareDx stock.

The Eulerpool Quality Score for CareDx is 3/10.

The ISIN of CareDx is US14167L1035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of CareDx is A118WG. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of CareDx is CDNA. The ticker symbol is used to trade CareDx shares on the stock exchange.

Fair ValueTerminal
56.74 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
499,086.73 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website caredx.com
Currency
USD
Initial public offering
Jul 17, 2014
ISIN
US14167L1035
Cusip
14167L103
Sedol
BP3YM74
Market capitalization
3.24 B USDMid Cap
52-Week Range
PEG
-8.39
P/E ratio
P/Ee 2026
52.63
P/Ee 2027
48.87
P/Ee 2028
34.26
P/Ee 2029
29.88
P/Ee 2030
23.01
P/S
P/Se
6.51
EV/EBIT
—
P/B Ratio
10.70
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-6.90 %
Last updated Oct 8, 2026, 5:54 AM

CareDx Ticker

DÜSSELDORF · 1K9.DUFRANKFURT · 1K9MUNICH · 1K9.MUNASDAQ · CDNANEW YORK ·

CareDx FIGI

CDNA:US · BBG006JS5785CDNA:UA · BBG006LCXWT8CDNA:UC · BBG006LCXWV5CDNA:UN · BBG006LCXWX3CDNA:UP · BBG006LCXWY2CDNA:UQ · BBG006LCXWZ1CDNA:UB · BBG006LCXX07CDNA:UM · BBG006LCXX25CDNA:UX · BBG006LCXX34CDNA:UD · BBG006LCXX98CDNA:UF · BBG006LCXXD3CDNA:VY · BBG006LCXXF1

All fundamentals and in-depth analysis of CareDx

Our stock analysis for CareDx stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CareDx. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.